Aktuelle Diagnostik und Therapie der pulmonalen Hypertonie

 

 Permissions and Reprints

Zusammenfassung

Krankheitsverständnis und Therapie der pulmonalen Hypertonie haben sich in den letzten Jahren grundlegend gewandelt. Für die pulmonal arterielle Hypertonie stehen mittlerweile mit Endothelin-Rezeptor-Antagonisten, Phosphodiesterase-5-Inhibitoren und Prostanoiden drei wirksame Substanzklassen zu Verfügung. Gleichzeitig werden auch Therapieverfahren für andere Formen der pulmonalen Hypertonie entwickelt. Entsprechend wichtig sind heute ein möglichst frühzeitiges Erkennen einer pulmonalen Hypertonie sowie die korrekte diagnostische Klassifikation als Voraussetzung einer gezielten und effektiven Behandlung. Dieser Artikel beschreibt moderne diagnostische Strategien sowie aktuelle Therapieprinzipien für die aus Sicht des Pneumologen wichtigsten Formen der pulmonalen Hypertonie. Die anschließenden CME-Fragen beziehen sich ausschließlich auf praxisrelevante Inhalte.

Literatur

• 1 Galie N, Torbicki A, Barst R. et al . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
  CrossrefPubMedGoogle Scholar
• 2 Chaouat A, Bugnet A S, Kadaoui N. et al . Severe pulmonary hypertension and chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2005;  172 189-194
  CrossrefPubMedGoogle Scholar
• 3 Resten A, Maitre S, Humbert M. et al . Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease.  AJR Am J Roentgenol. 2004;  183 65-70
  CrossrefPubMedGoogle Scholar
• 4 Rabiller A, Jais X, Hamid A. et al . Occult alveolar haemorrhage in pulmonary veno-occlusive disease.  Eur Respir J. 2006;  27 108-113
  CrossrefPubMedGoogle Scholar
• 5 Sitbon O, Humbert M, Nunes H. et al . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788
  CrossrefPubMedGoogle Scholar
• 6 Wensel R, Opitz C F, Anker S D. et al . Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.  Circulation. 2002;  106 319-324
  CrossrefPubMedGoogle Scholar
• 7 Nagaya N, Nishikimi T, Uematsu M. et al . Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.  Circulation. 2000;  102 865-870
  CrossrefPubMedGoogle Scholar
• 8 Leuchte H H, Holzapfel M, Baumgartner R A. et al . Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 764-770
  CrossrefPubMedGoogle Scholar
• 9 Simonneau G, Galie N, Rubin L J. et al . Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 5S-12S
  CrossrefPubMedGoogle Scholar
• 10 Sitbon O, Humbert M, Jais X. et al . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
  CrossrefPubMedGoogle Scholar
• 11 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
  CrossrefPubMedGoogle Scholar
• 12 Humbert M, Morrell N W, Archer S L. et al . Cellular and molecular pathobiology of pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43 13S-24S
  CrossrefPubMedGoogle Scholar
• 13 Hoeper M M. Drug treatment of pulmonary arterial hypertension: current and future agents.  Drugs. 2005;  65 1337-1354
  CrossrefPubMedGoogle Scholar
• 14 Farber H W, Loscalzo J. Pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1655-1665
  CrossrefPubMedGoogle Scholar
• 15 Barst R J, Rubin L J, Long W A. et al . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med. 1996;  334 296-302
  CrossrefPubMedGoogle Scholar
• 16 Hoeper M M, Spiekerkoetter E, Westerkamp V. et al . Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension.  Eur Respir J. 2002;  20 339-343
  CrossrefPubMedGoogle Scholar
• 17 Gomberg-Maitland M, Tapson V F, Benza R L. et al . Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension.  Am J Respir Crit Care Med. 2005;  172 1586-1589
  CrossrefPubMedGoogle Scholar
• 18 Olschewski H, Simonneau G, Galie N. et al . Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
  CrossrefPubMedGoogle Scholar
• 19 Opitz C F, Wensel R, Winkler J. et al . Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.  Eur Heart J. 2005;  26 1895-1902
  CrossrefPubMedGoogle Scholar
• 20 Channick R N, Simonneau G, Sitbon O. et al . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
  CrossrefPubMedGoogle Scholar
• 21 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
  CrossrefPubMedGoogle Scholar
• 22 Sitbon O, Gressin V, Speich R. et al . Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  170 1212-1217
  CrossrefPubMedGoogle Scholar
• 23 Hoeper M M, Halank M, Marx C. et al . Bosentan therapy for portopulmonary hypertension.  Eur Respir J. 2005;  25 502-508
  CrossrefPubMedGoogle Scholar
• 24 McLaughlin V V, Sitbon O, Badesch D B. et al . Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
  CrossrefPubMedGoogle Scholar
• 25 Sitbon O, McLaughlin V V, Badesch D B. et al . Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.  Thorax. 2005;  60 1025-1030
  CrossrefPubMedGoogle Scholar
• 26 Barst R J, Langleben D, Frost A. et al . Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
  CrossrefPubMedGoogle Scholar
• 27 Galie N, Badesch D, Oudiz R. et al . Ambrisentan therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2005;  46 529-535
  CrossrefPubMedGoogle Scholar
• 28 Galie N, Ghofrani H A, Torbicki A. et al . Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension.  N Engl J Med. 2005;  353 2148-2157
  CrossrefPubMedGoogle Scholar
• 29 Hoeper M M, Welte T. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2006;  354 1091-1093; author reply 1091 - 1093
  CrossrefPubMedGoogle Scholar
• 30 Ghofrani H A, Rose F, Schermuly R T. et al . Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
  CrossrefPubMedGoogle Scholar
• 31 Hoeper M M, Faulenbach C, Golpon H. et al . Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
  CrossrefPubMedGoogle Scholar
• 32 Hoeper M M, Taha N, Bekjarova A. et al . Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
  CrossrefPubMedGoogle Scholar
• 33 Hoeper M M, Markevych I, Spiekerkoetter E. et al . Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.  Eur Respir J. 2005;  26 858-863
  CrossrefPubMedGoogle Scholar
• 34 Scharf S M, Iqbal M, Keller C. et al . Hemodynamic characterization of patients with severe emphysema.  Am J Respir Crit Care Med. 2002;  166 314-322
  CrossrefPubMedGoogle Scholar
• 35 Kessler R, Faller M, Weitzenblum E. et al . “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.  Am J Respir Crit Care Med. 2001;  164 219-224
  CrossrefPubMedGoogle Scholar
• 36 Barbera J A, Peinado V I, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease.  Eur Respir J. 2003;  21 892-905
  CrossrefPubMedGoogle Scholar
• 37 Weitzenblum E, Apprill M, Oswald M. et al . Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema.  Chest. 1994;  105 1377-1382
  CrossrefPubMedGoogle Scholar
• 38 Agostoni P, Doria E, Galli C. et al . Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1989;  139 120-125
  CrossrefPubMedGoogle Scholar
• 39 Nadrous H F, Pellikka P A, Krowka M J. et al . Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.  Chest. 2005;  128 2393-2399
  CrossrefPubMedGoogle Scholar
• 40 Olschewski H, Ghofrani H A, Walmrath D. et al . Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.  Am J Respir Crit Care Med. 1999;  160 600-607
  CrossrefPubMedGoogle Scholar
• 41 Ghofrani H A, Wiedemann R, Rose F. et al . Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.  Lancet. 2002;  360 895-900
  CrossrefPubMedGoogle Scholar
• 42 Hoeper M M, Mayer E, Simonneau G. et al . Chronic thromboembolic pulmonary hypertension.  Circulation. 2006;  113 2011-2020
  CrossrefPubMedGoogle Scholar
• 43 Dartevelle P, Fadel E, Mussot S. et al . Chronic thromboembolic pulmonary hypertension.  Eur Respir J. 2004;  23 637-648
  CrossrefPubMedGoogle Scholar
• 44 Jamieson S W, Kapelanski D P, Sakakibara N. et al . Pulmonary endarterectomy: experience and lessons learned in 1,500 cases.  Ann Thorac Surg. 2003;  76 1457-1462; discussion 1462 - 1464
  CrossrefPubMedGoogle Scholar
• 45 Ghofrani H A, Schermuly R T, Rose F. et al . Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.  Am J Respir Crit Care Med. 2003;  167 1139-1141
  PubMedGoogle Scholar
• 46 Hoeper M M, Kramm T, Wilkens H. et al . Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.  Chest. 2005;  128 2363-2367
  CrossrefPubMedGoogle Scholar
• 47 Bonderman D, Nowotny R, Skoro-Sajer N. et al . Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.  Chest. 2005;  128 2599-2603
  CrossrefPubMedGoogle Scholar
• 48 Hughes R, George P, Parameshwar J. et al . Bosentan in inoperable chronic thromboembolic pulmonary hypertension.  Thorax. 2005;  60 707
  CrossrefPubMedGoogle Scholar

Prof. Dr. med. Marius Hoeper

Medizinische Hochschule Hannover · Abteilung Pneumologie

Carl-Neuberg-Str. 1

30625 Hannover

Email: hoeper.marius@mh-hannover.de